Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Dias, Ananda T ^a   Cintra, Amanda S ^b   Frossard, Jéssica C ^b   Palomino, Zaira ^c   Casarini, Dulce E ^c   Gomes, Isabele B S ^a   Balarini, Camille M ^d   Gava, Agata L ^a   Campagnaro, Bianca P ^e   Pereira, Thiago M C ^e,f   Meyrelles, Silvana S ^a   Vasquez, Elisardo C ^a,b,e  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^e UNIVERSIDADE VILA VELHA   (Brazil)

^f Federal Institute of Education   (Brazil)

Author keywords

2K1C; Angiotensin; Endothelial function; Oxidative stress; Renovascular hypertension; Sildenafil

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SILDENAFIL; ANGIOTENSIN DERIVATIVE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CELL ISOLATION; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME SYNTHESIS; HEART RATE; HEMODYNAMICS; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; TREATMENT RESPONSE; ANIMAL; BLOOD; BLOOD PRESSURE; C57BL MOUSE; ENZYMOLOGY; FLOW CYTOMETRY; METABOLISM; ORGAN SIZE; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANGIOTENSINS; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; HEART RATE; HYPERTENSION, RENOVASCULAR; MICE; MICE, INBRED C57BL; ORGAN SIZE; OXIDATIVE STRESS; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 84908118678     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0250-x     Document Type: Article

References (68)

1. Chokshi NP, Grossman E, Messerli FH. Blood pressure and diabetes: vicious twins. Heart 2013, 99(8):577-585. 10.1136/heartjnl-2012-302029, 23434624.
2. Silva BR, Pernomian L, Bendhack LM: Contribution of oxidative stress to endothelial dysfunction in hypertension.Front Physiol 2012, 3:441.
3. Campagnaro BP, Gava AL, Meyrelles SS, Vasquez EC: Cardiac-autonomic imbalance and baroreflex dysfunction in the renovascular angiotensin-dependent hypertensive mouse.Int J Hypertens 2012, 2012:968123.
4. Faselis C, Doumas M, Papademetriou V: Common secondary causes of resistant hypertension and rational for treatment.Int J Hypertens 2011, 2011:236239.
5. Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD. Unraveling the mystery of Goldblatt Hypertension. News Physiol Sci 1998, 13:170-176. 11390784.
6. Piecha G, Wiecek A, Januszewicz A. Epidemiology and optimal management in patients with renal artery stenosis. J Nephrol 2012, 25(6):872-878. 10.5301/jn.5000206, 23023722.
7. Elliott WJ. Renovascular hypertension: an update. J Clin Hypertens 2008, 10(7):522-533. 10.1111/j.1751-7176.2008.07788.x.
8. Carey RM. Resistant hypertension. Hypertension 2013, 61(4):746-750. 10.1161/HYPERTENSIONAHA.111.00601, 23438928.
9. Vassallo DV, Vasquez EC, Cabral AM. Contractile performance of papillary muscles of renovascular hypertensive and isoproterenol-pretreated rats. Pharmacol Res Commun 1988, 20(1):61-72. 10.1016/S0031-6989(88)80607-6, 3375290.
10. Abreu GR, Futuro-Neto HA, Cabral AM, Vasquez EC. L-arginine restores the effect of ouabain on baroreceptor activity and prevents hypertension. Hypertension 1999, 34(4 Pt 2):729-732. 10.1161/01.HYP.34.4.729, 10523350.
11. Pereira TM, Balarini CM, Silva IV, Cabral AM, Vasquez EC, Meyrelles SS. Endogenous angiotensin II modulates nNOS expression in renovascular hypertension. Braz J Med Biol Res 2009, 42(7):685-691. 10.1590/S0100-879X2009000700014, 19578649.
12. Nogueira BV, Peotta VA, Meyrelles SS, Vasquez EC. Evaluation of aortic remodeling in apolipoprotein E-deficient mice and renovascular hypertensive mice. Arch Med Res 2007, 38(8):816-821. 10.1016/j.arcmed.2007.06.005, 17923260.
13. Gava AL, Peotta VA, Cabral AM, Vasquez EC, Meyrelles SS. Overexpression of eNOS prevents the development of renovascular hypertension in mice. Can J Physiol Pharmacol 2008, 86(7):458-464. 10.1139/Y08-044, 18641695.
14. Peotta VA, Gava AL, Vasquez EC, Meyrelles SS. Evaluation of baroreflex control of heart rate in renovascular hypertensive mice. Can J Physiol Pharmacol 2007, 85(8):761-766. 10.1139/Y07-067, 17901885.
15. Arruda RM, Peotta VA, Meyrelles SS, Vasquez EC. Evaluation of vascular function in apolipoprotein E knockout mice with angiotensin-dependent renovascular hypertension. Hypertension 2005, 46:932-936. 10.1161/01.HYP.0000182154.61862.52, 16087779.
16. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 2013, 216(2):R1-R17. 10.1530/JOE-12-0341, 23092879.
17. Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 2005, 38:499-507. 10.1590/S0100-879X2005000400003, 15962175.
18. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 2006, 47(3):515-521. 10.1161/01.HYP.0000196268.08909.fb, 16365192.
19. Sihn G, Rousselle A, Vilianovitch L, Burckle C, Bader M. Physiology of the (pro)renin receptor: Wnt of change?. Kidney Int 2010, 78(3):246-256. 10.1038/ki.2010.151, 20505655.
20. Nogueira BV, Palomino Z, Porto ML, Balarini CM, Pereira TM, Baldo MP, Casarini DE, Meyrelles SS, Vasquez EC. Granulocyte colony stimulating factor prevents kidney infarction and attenuates renovascular hypertension. Cell Physiol Biochem 2012, 29(1-2):143-152. 10.1159/000337595, 22415083.
21. Dias AT, Rodrigues BP, Porto ML, Gava AL, Balarini CM, Freitas FP, Palomino Z, Casarini DE, Campagnaro BP, Pereira TM, Meyrelles SS, Vasquez EC: Sildenafil ameliorates oxidative stress and DNA damage in the stenotic kidneys in mice with renovascular hypertension.J Transl Med 2014, 12:35.
22. Meyrelles SS, Peotta VA, Pereira TM, Vasquez EC: Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging.Lipids Health Dis 2011, 10:211.
23. Cola MS, Gava AL, Meyrelles SS, Vasquez EC: Endothelial dysfunction of resistance vessels in female apolipoprotein E-deficient mice.Lipids Health Dis 2010, 9:51.
24. de Carvalho MH, Nigro D, Scivoletto R, Barbeiro HV, de Oliveira MA, de Nucci G, Fortes ZB. Comparison of the effect of endothelin on microvessels and macrovessels in Goldblatt II and deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1990, 15(2 Suppl):I68-I71. 10.1161/01.HYP.15.2_Suppl.I68, 2404864.
25. Fortes ZB, Costa SG, Nigro D, Scivoletto R, de Oliveira MA, de Carvalho MH. Effect of indomethacin on the microvessel reactivity of two-kidney, one-clip hypertensive rats. Arch Int Pharmacodyn Ther 1992, 316:75-89. 1530375.
26. Raja SG, Nayak SH. Sildenafil: emerging cardiovascular indications. Ann Thorac Surg 2004, 78(4):1496-1506. 10.1016/j.athoracsur.2004.02.125, 15464535.
27. Balarini CM, Leal MA, Gomes IBS, Pereira TMC, Gava AL, Meyrelles SS, Vasquez EC: Sildenafil restores endothelial function in the apolipoprotein E knockout mouse.J Transl Med 2013, 11:3.
28. Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009, 26(9):813-825. 10.1007/s12325-009-0064-z, 19768639.
29. Rodrigues BP, Campagnaro BP, Balarini CM, Pereira TM, Meyrelles SS, Vasquez EC: Sildenafil ameliorates biomarkers of genotoxicity in an experimental model of spontaneous atherosclerosis.Lipids Health Dis 2013, 28:12. 128.
30. Campagnaro BP, Tonini CL, Nogueira BV, Casarini DE, Vasquez EC, Meyrelles SS: DNA damage and augmented oxidative stress in bone marrow mononuclear cells from angiotensin-dependent hypertensive mice.Int J Hypertens 2013, 2013:305202.
31. Campagnaro BP, Tonini CL, Doche LM, Nogueira BV, Vasquez EC, Meyrelles SS. Renovascular hypertension leads to DNA damage and apoptosis in bone marrow cells. DNA Cell Biol 2013, 32(8):458-466. 10.1089/dna.2013.2065, 23786322.
32. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999, 29(3):297-310. 10.1080/004982599238687, 10219969.
33. Mattson DL. Comparison of arterial blood pressure in different strains of mice. Am J Hypertens 2001, 14(5 Pt 1):405-408. 10.1016/S0895-7061(00)01285-1, 11368457.
34. Prieto MC, González-Villalobos RA, Botros FT, Martin VL, Pagán J, Satou R, Lara LS, Feng Y, Fernandes FB, Kobori H, Casarini DE, Navar LG. Reciprocal changes in renal ACE/Ang II and ACE2/ANG 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. Am J Physiol Renal Physiol 2011, 300:F749-F755. 10.1152/ajprenal.00383.2009, 21209009.
35. Santos RA, Ferreira AJ. Angiotensin-(1-7) and the renin-angiotensin system. Curr Opinion Nephrol Hypertens 2007, 16:122-128. 10.1097/MNH.0b013e328031f362.
36. Sadjadi J, Kramer GL, Yu CH, Burress Welborn M, Chappell MC, Gregory Modrall J. Angiotensin converting enzyme-independent angiotensin ii production by chymase is up-regulated in the ischemic kidney in renovascular hypertension. J Surg Res 2005, 127(2):65-69. 10.1016/j.jss.2005.02.031, 15869764.
37. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition andangiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005, 111(20):2605-2610. 10.1161/CIRCULATIONAHA.104.510461, 15897343.
38. Gallagher PE, Chappell MC, Ferrario CM, Tallant EA. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 2006, 290(2):C420-C426. 10.1152/ajpcell.00409.2004, 16176966.
39. Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI: Update on the angiotensin converting enzyme 2-angiotensin (1-7)-Mas receptor axis: fetal programing, sex differences, and intracellular pathways.Front Endocrinol (Lausanne) 2014, 4:201.
40. Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 2008, 172(5):1174-1183. 10.2353/ajpath.2008.070762, 18403595.
41. Hartono SP, Knudsen BE, Zubair AS, Nath KA, Textor SJ, Lerman LO, Grande JP. Redox signaling is an early event in the pathogenesis of renovascular hypertension. Int J Mol Sci 2013, 14(9):18640-18656. 10.3390/ijms140918640, 24025423.
42. Cervenka L, Vanecková I, Husková Z, Vanourková Z, Erbanová M, Thumová M, Skaroupková P, Opocenský M, Malý J, Chábová VC, Tesar V, Bürgelová M, Viklický O, Teplan V, Zelízko M, Kramer HJ, Navar LG. Pivotal role of angiotensin II receptor subtype 1A in the development of two-kidney, one-clip hypertension: study in angiotensin II receptor subtype 1A knockout mice. J Hypertens 2008, 26(7):1379-1389. 10.1097/HJH.0b013e3282fe6eaa, 18551014.
43. Rakušan D, Bürgelová M, Vaněčková I, Vaňourková Z, Husková Z, Skaroupková P, Mrázová I, Opočenský M, Kramer HJ, Netuka I, Malý J, Alenina N, Bader M, Santos RA, Cervenka L. Knockout of angiotensin 1-7 receptor Mas worsens the course of two-kidney, one-clip Goldblatt hypertension: roles of nitric oxide deficiency and enhanced vascular responsiveness to angiotensin II. Kidney Blood Press Res 2010, 33(6):476-488. 10.1159/000320689, 21071955.
44. Wiesel P, Mazzolai L, Nussberger J, Pedrazzini T. Two-kidney, one clip and one-kidney, one clip hypertension in mice. Hypertension 1997, 29:1025-1030. 10.1161/01.HYP.29.4.1025, 9095094.
45. Salguero G, Akin E, Templin C, Kotlarz D, Doerries C, Landmesser U, Grote K, Schieffer B. Renovascular hypertension by two-kidney one-clip enhances endothelial progenitor cell mobilization in a p47phox-dependent manner. J Hypertens 2008, 26(2):257-268. 10.1097/HJH.0b013e3282f09f79, 18192840.
46. Castro MM, Rizzi E, Rascado RR, Nagassaki S, Bendhack LM, Tanus-Santos JE. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur J Pharmacol 2004, 498(1-3):189-194. 10.1016/j.ejphar.2004.07.051, 15363994.
47. Neto-Neves EM, Dias-Junior CA, Uzuelli JA, Pereira RP, Spiller F, Czaikoski PG, Tanus-Santos JE. Sildenafil improves the beneficial hemodynamic effects exerted by atorvastatin during acute pulmonary thromboembolism. Eur J Pharmacol 2011, 670(2-3):554-560. 10.1016/j.ejphar.2011.09.018, 21946107.
48. Guimarães DA, Rizzi E, Ceron CS, Pinheiro LC, Gerlach RF, Tanus-Santos JE. Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension. Redox Biol 2013, 1(1):578-585. 10.1016/j.redox.2013.11.004, 24363994.
49. Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, Costa-Fraga FP, Fraga-Silva RA, Cojocaru G, Cohen Y, Bader M, de Almeida AP, Rotman G, Santos RA. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 2010, 56(1):112-120. 10.1161/HYPERTENSIONAHA.110.152942, 20479330.
50. Shah A, Oh YB, Lee SH, Lim JM, Kim SH. Angiotensin-(1-7) attenuates hypertension in exercise-trained renal hypertensive rats. Am J Physiol Heart Circ Physiol 2012, 302(11):H2372-H2380. 10.1152/ajpheart.00846.2011, 22467306.
51. Andresern BT, Shome K, Jackson EK, Romero GG. AT2 receptors cross talk with AT1 receptors through a nitric oxide- and RhoA-dependent mechanism resulting in decreased phospholipase D activity. Am J Physiol Renal Physiol 2005, 288(4):F763-F770. 10.1152/ajprenal.00323.2004.
52. Babu CS, Kalaivani P, Ranju V, Sathiya S, Anbarasi C, Mahadevan MV, Vijayakumar H, Sunil AG, Thanikachalam S. Venthamarai chooranam, a polyherbal Siddha medicine, alleviates hypertension via AT1R and eNOS signaling pathway in 2K1C hypertensive rats. Exp Biol Med (Maywood) 2014, 239(6):758-769. 10.1177/1535370214525317.
53. Hiyoshi H, Yayama K, Takano M, Okamoto H. Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. Hypertension 2005, 45(5):967-973. 10.1161/01.HYP.0000164571.77710.19, 15837834.
54. Blanch GT, Freiria-Oliveira AH, Speretta GF, Carrera EJ, Li H, Speth RC, Colombari E, Sumners C, Colombari DS: Increased Expression of Angiotensin II Type 2 Receptors in the Solitary-Vagal Complex Blunts Renovascular Hypertension.Hypertension 2014, (Epub ahead of print).
55. Milman HA, Arnold SB. Neurologic, psychological, and aggressive disturbances with sildenafil. Ann Pharmacother 2002, 36(7-8):1129-1134. 10.1345/aph.1A402, 12086542.
56. Fazan R Jr, Huber DA, Silva CA, da Silva VJ D, Salgado MC, Salgado HC: Sildenafil acts on the central nervous system increasing sympathetic activity.J Appl Physiol (1985) 2008, 104(6):1683.
57. Dopp JM, Agapitov AV, Sinkey CA, Haynes WG, Phillips BG. Sildenafil increases sympathetically mediated vascular tone in humans. Am J Hypertens 2013, 26(6):762-769. 10.1093/ajh/hpt018, 23443723.
58. Neves C, Tufik S, Chediek F, Poyares D, Cintra F, Roizenblatt M, Abrantes F, Monteiro MA, Roizenblatt S. Effects of sildenafil on autonomic nervous function during sleep in obstructive sleep apnea. Clinics (Sao Paulo) 2010, 65(4):393-400. 10.1590/S1807-59322010000400008.
59. Giachini FR, Lima VV, Carneiro FS, Tostes RC, Webb RC. Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1. Hypertension 2011, 57(3):655-663. 10.1161/HYPERTENSIONAHA.110.164327, 21282562.
60. Schäfer A, Fraccarollo D, Pförtsch S, Flierl U, Vogt C, PfrAng J, Kobsar A, Renné T, Eigenthaler M, Ertl G, Bauersachs J. Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. Brit J Pharmacol 2008, 153(5):886-893. 10.1038/sj.bjp.0707459.
61. Lee J, Choi KC, Yeum CH, Kim W, Yoo K, Park JW, Yoon PJ. Impairment of endothelium-dependent vasorelaxation in chronic two-kidney, one clip hypertensive rats. Nephrol Dial Transplant 1995, 10(5):619-623. 7566572.
62. Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T, Nagao T, Egashira K, Fujishima M, Takeshita A. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 1996, 28(5):703-711. 10.1097/00005344-199611000-00014, 8945685.
63. Wang D, Chabrashvili T, Borrego L, Aslam S, Umans JG. Angiotensin II infusion alters vascular function in mouse resistance vessels: roles of O and endothelium. J Vasc Res 2006, 43:109-119. 10.1159/000089969, 16340215.
64. Dohi Y, Criscione L, Lüscher TF. Renovascular hypertension impairs formation of endothelium-derived relaxing factors and sensitivity to endothelin-1 in resistance arteries. Br J Pharmacol 1991, 104(2):349-354. 10.1111/j.1476-5381.1991.tb12434.x, 1797302.
65. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 2004, 109(14):1795-1801. 10.1161/01.CIR.0000124223.00113.A4, 15037533.
66. Zou M, Anges C. Cell-cell interaction between platelets and IL-1 beta-stimulated vascular smooth muscle cells in synthesis of thromboxane A2. Prostaglandins Leukot Essent Fatty Acids 1997, 56(2):85-91. 10.1016/S0952-3278(97)90502-0, 9051715.
67. Lee KC, Yang YY, Huang YT, Lee FY, Hou MC, Lin HC, Lee SD. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability. Clin Sci (Lond) 2010, 119(1):45-55. 10.1042/CS20090601.
68. Lohse MJ, Förstermann U, Schmidt HH. Pharmacology of NO: cGMP signal transduction. Naunyn Schmiedebergs Arch Pharmacol 1998, 358(1):111-112. 10.1007/PL00005230, 9721011.